The lack of correlation between clinical signs and symptoms of dry eye disease makes diagnosing and treating patients a challenge. Now there is a solution to this problem.
InflammaDry® is the first and only, rapid result, in-office test that detects elevated levels of MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with dry eye disease.1 All other dry eye tests measure tear production and stability. Using a simple 4-step process, InflammaDry® recognizes elevated levels of MMP-9, to identify patients that may otherwise be missed with other dry eye testing methods.
Commit to making the right diagnosis, with an easy-to-use, in-office test, that gives accurate results in 10 minutes. For your convenience, InflammaDry® is available in two different package configurations.
MMP-9 is a more sensitive diagnostic marker for dry eye than clinical signs alone.
Inflammation is present before the clinical signs of dry eye.
Increased MMP-9 activity in dry eyes may contribute to deranged corneal epithelial barrier function, increased corneal desquamation, and corneal surface irregularity.
InflammaDry® provides highly accurate results: 85% sensitivity, 94% specificity
Preoperatively identifying and treating patients with dry eye disease leads to many clinical advantages, such as improved surgical outcomes, reduced complications, and better patient care.
Dry eye disease may require an extensive treatment plan and continuous therapy.
Artificial tears and punctal occlusion may improve signs and symptoms, while helping to decrease visual irritation.
Anti-inflammatory therapies, such as cyclosporine, corticosteroids, and doxycycline have been
shown to decrease MMP-9 activity.
InflammaDry® test results are achieved in just 10 minutes, allowing a diagnosis and treatment plan to be established with the patient before they leave the office.